In this issue:
- Sacituzumab tirumotecan vs docetaxel after prior treatment failure
- Sacituzumab govitecan as second-line therapy
- Real-world outcomes of treatment strategies after durvalumab
- Longer-term follow-up of single-agent divarasib
- Systemic anti-cancer treatment in Māori patients
- Incidental findings during LDCT lung cancer screening
- National variation in the treatment of lung cancer in NZ
- Polygenic risk score and disease incidence and mortality
- Age-related survival differences based on real-world data
Please login below to download this issue (PDF)